Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration

Tereza Cristina Moreira Kanadani, Carlos Eduardo Dos Reis Veloso, Syril Dorairaj, Márcio Bittar Nehemy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To investigate the effect of vitreomacular adhesion (VMA) on the outcome of antiangiogenic treatment for neovascular age-related macular degeneration (AMD). Methods: Ninety-nine eyes of 83 patients were used in our cohort study. We prospectively evaluated best corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with neovascular AMD at baseline and 1, 2, 3, 6, and 12 months after treatment with anti-vascular endothelial growth factor (anti-VEGF) agents. All patients were stratified by spectral domain optical coherence tomography into 2 groups (i.e., VMA[+] and VMA[-]) according to the presence or absence of VMA, and the response to treatment was evaluated. Results: Fifty-four eyes (54.5%) were included in the VMA(-) group and 45 eyes (45.5%) comprised the VMA(+) group. In paired comparisons of mean BCVA between baseline and each follow-up visit (1, 2, 3, 6, and 12 months), the VMA(-) group showed statistically significant improvement at 1, 2, and 3 months compared to baseline, and BCVA significantly improved only at 3 months in the VMA(+) group. For both groups, paired comparisons of CRT showed a statistically significant decrease when data obtained at 1, 2, 3, 6, and 12 months were compared to baseline values (p < 0.05). Conclusions: Posterior VMA is associated with a worse short-term outcome in patients with neovascular AMD treated with anti-VEGF agents.

Original languageEnglish (US)
Pages (from-to)18-26
Number of pages9
JournalOphthalmic Research
Volume58
Issue number1
DOIs
StatePublished - Jun 1 2017

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Visual Acuity
Matched-Pair Analysis
Optical Coherence Tomography
Therapeutics
Cohort Studies

Keywords

  • Antiangiogenic treatment
  • Neovascular age-related macular degeneration
  • Vitreomacular adhesion

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. / Kanadani, Tereza Cristina Moreira; Dos Reis Veloso, Carlos Eduardo; Dorairaj, Syril; Nehemy, Márcio Bittar.

In: Ophthalmic Research, Vol. 58, No. 1, 01.06.2017, p. 18-26.

Research output: Contribution to journalArticle

Kanadani, Tereza Cristina Moreira ; Dos Reis Veloso, Carlos Eduardo ; Dorairaj, Syril ; Nehemy, Márcio Bittar. / Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. In: Ophthalmic Research. 2017 ; Vol. 58, No. 1. pp. 18-26.
@article{3034b751eacd46d3befef961df5a0c6a,
title = "Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration",
abstract = "Purpose: To investigate the effect of vitreomacular adhesion (VMA) on the outcome of antiangiogenic treatment for neovascular age-related macular degeneration (AMD). Methods: Ninety-nine eyes of 83 patients were used in our cohort study. We prospectively evaluated best corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with neovascular AMD at baseline and 1, 2, 3, 6, and 12 months after treatment with anti-vascular endothelial growth factor (anti-VEGF) agents. All patients were stratified by spectral domain optical coherence tomography into 2 groups (i.e., VMA[+] and VMA[-]) according to the presence or absence of VMA, and the response to treatment was evaluated. Results: Fifty-four eyes (54.5{\%}) were included in the VMA(-) group and 45 eyes (45.5{\%}) comprised the VMA(+) group. In paired comparisons of mean BCVA between baseline and each follow-up visit (1, 2, 3, 6, and 12 months), the VMA(-) group showed statistically significant improvement at 1, 2, and 3 months compared to baseline, and BCVA significantly improved only at 3 months in the VMA(+) group. For both groups, paired comparisons of CRT showed a statistically significant decrease when data obtained at 1, 2, 3, 6, and 12 months were compared to baseline values (p < 0.05). Conclusions: Posterior VMA is associated with a worse short-term outcome in patients with neovascular AMD treated with anti-VEGF agents.",
keywords = "Antiangiogenic treatment, Neovascular age-related macular degeneration, Vitreomacular adhesion",
author = "Kanadani, {Tereza Cristina Moreira} and {Dos Reis Veloso}, {Carlos Eduardo} and Syril Dorairaj and Nehemy, {M{\'a}rcio Bittar}",
year = "2017",
month = "6",
day = "1",
doi = "10.1159/000459626",
language = "English (US)",
volume = "58",
pages = "18--26",
journal = "Ophthalmic Research",
issn = "0030-3747",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration

AU - Kanadani, Tereza Cristina Moreira

AU - Dos Reis Veloso, Carlos Eduardo

AU - Dorairaj, Syril

AU - Nehemy, Márcio Bittar

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Purpose: To investigate the effect of vitreomacular adhesion (VMA) on the outcome of antiangiogenic treatment for neovascular age-related macular degeneration (AMD). Methods: Ninety-nine eyes of 83 patients were used in our cohort study. We prospectively evaluated best corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with neovascular AMD at baseline and 1, 2, 3, 6, and 12 months after treatment with anti-vascular endothelial growth factor (anti-VEGF) agents. All patients were stratified by spectral domain optical coherence tomography into 2 groups (i.e., VMA[+] and VMA[-]) according to the presence or absence of VMA, and the response to treatment was evaluated. Results: Fifty-four eyes (54.5%) were included in the VMA(-) group and 45 eyes (45.5%) comprised the VMA(+) group. In paired comparisons of mean BCVA between baseline and each follow-up visit (1, 2, 3, 6, and 12 months), the VMA(-) group showed statistically significant improvement at 1, 2, and 3 months compared to baseline, and BCVA significantly improved only at 3 months in the VMA(+) group. For both groups, paired comparisons of CRT showed a statistically significant decrease when data obtained at 1, 2, 3, 6, and 12 months were compared to baseline values (p < 0.05). Conclusions: Posterior VMA is associated with a worse short-term outcome in patients with neovascular AMD treated with anti-VEGF agents.

AB - Purpose: To investigate the effect of vitreomacular adhesion (VMA) on the outcome of antiangiogenic treatment for neovascular age-related macular degeneration (AMD). Methods: Ninety-nine eyes of 83 patients were used in our cohort study. We prospectively evaluated best corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with neovascular AMD at baseline and 1, 2, 3, 6, and 12 months after treatment with anti-vascular endothelial growth factor (anti-VEGF) agents. All patients were stratified by spectral domain optical coherence tomography into 2 groups (i.e., VMA[+] and VMA[-]) according to the presence or absence of VMA, and the response to treatment was evaluated. Results: Fifty-four eyes (54.5%) were included in the VMA(-) group and 45 eyes (45.5%) comprised the VMA(+) group. In paired comparisons of mean BCVA between baseline and each follow-up visit (1, 2, 3, 6, and 12 months), the VMA(-) group showed statistically significant improvement at 1, 2, and 3 months compared to baseline, and BCVA significantly improved only at 3 months in the VMA(+) group. For both groups, paired comparisons of CRT showed a statistically significant decrease when data obtained at 1, 2, 3, 6, and 12 months were compared to baseline values (p < 0.05). Conclusions: Posterior VMA is associated with a worse short-term outcome in patients with neovascular AMD treated with anti-VEGF agents.

KW - Antiangiogenic treatment

KW - Neovascular age-related macular degeneration

KW - Vitreomacular adhesion

UR - http://www.scopus.com/inward/record.url?scp=85015911810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015911810&partnerID=8YFLogxK

U2 - 10.1159/000459626

DO - 10.1159/000459626

M3 - Article

C2 - 28301850

AN - SCOPUS:85015911810

VL - 58

SP - 18

EP - 26

JO - Ophthalmic Research

JF - Ophthalmic Research

SN - 0030-3747

IS - 1

ER -